ViroGates A/S
ViroGates is an international Medtech company founded in 2001, based in Denmark, specializing in the development of the biomarker suPAR for prognostic health assessment across various diseases. The company offers rapid, reliable tests for measuring suPAR levels to support clinical decision-making, risk stratification, and personalized care in healthcare settings, including emergency departments, hospitals, and research. ViroGates aims to improve patient outcomes, reduce healthcare costs, and contribute to global health initiatives through its innovative diagnostic solutions and commitment to societal responsibility.
Industries
Nr. of Employees
small (1-50)
ViroGates A/S
Banevaenget 13, DK-3460 Birkeroed, Denmark
Products
Point-of-care rapid suPAR test
A rapid, minimally invasive immunoassay intended for point-of-care use to provide fast suPAR results for triage and immediate clinical decision-making.
Automated turbidimetric latex suPAR assay for clinical analyzers
A turbidimetric latex immunoassay formatted for use on automated clinical chemistry analyzers to enable high-throughput suPAR measurement in central laboratories.
ELISA-based suPAR assay for research and clinical use
A laboratory ELISA kit for quantification of suPAR in serum and plasma for research, population studies and clinical measurements used in algorithm development.
Point-of-care rapid suPAR test
A rapid, minimally invasive immunoassay intended for point-of-care use to provide fast suPAR results for triage and immediate clinical decision-making.
Automated turbidimetric latex suPAR assay for clinical analyzers
A turbidimetric latex immunoassay formatted for use on automated clinical chemistry analyzers to enable high-throughput suPAR measurement in central laboratories.
ELISA-based suPAR assay for research and clinical use
A laboratory ELISA kit for quantification of suPAR in serum and plasma for research, population studies and clinical measurements used in algorithm development.
Services
Consulting and technical support to integrate suPAR testing into emergency-department triage and central-laboratory workflows, including assay validation and turnaround-time optimization.
Guidance for adverse-event reporting and regulatory compliance related to in vitro diagnostic products.
Provision of assays and data tools to support patient selection, monitoring, and biomarker-driven endpoints in clinical studies.
Consulting and technical support to integrate suPAR testing into emergency-department triage and central-laboratory workflows, including assay validation and turnaround-time optimization.
Guidance for adverse-event reporting and regulatory compliance related to in vitro diagnostic products.
Provision of assays and data tools to support patient selection, monitoring, and biomarker-driven endpoints in clinical studies.
Expertise Areas
- Prognostic biomarker applications in acute care and emergency medicine
- Diagnostic immunoassay development and validation
- Clinical laboratory integration and workflow optimization
- Biomarker-driven patient stratification for clinical trials
Key Technologies
- Enzyme-linked immunosorbent assay (ELISA)
- Turbidimetric latex immunoassay
- Point-of-care rapid immunoassay
- Integration with automated clinical chemistry analyzers